Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:30 a.m. ET in New York.
A live webcast will stream via the investor section of www.beamtx.com and remain archived for 60 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BEAM
On the day this news was published, BEAM gained 0.85%, reflecting a mild positive market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $26M to the company's valuation, bringing the market cap to $3.13B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Clinical data update | Positive | -0.5% | Updated BEACON biomarker data for risto-cel in sickle cell disease. |
| May 07 | Earnings and pipeline | Positive | -2.7% | Q1 2026 results plus BEAM-302 dose selection and BLA timing for risto-cel. |
| Apr 01 | Clinical trial publication | Positive | +1.8% | NEJM publication of BEACON Phase 1/2 data for risto-cel in SCD. |
| Mar 25 | Clinical data update | Positive | -3.5% | Updated Phase 1/2 BEAM-302 AATD data supporting advancement to pivotal stage. |
| Feb 24 | Earnings and pipeline | Positive | +14.0% | Q4 2025 results, new PKU program BEAM-304, and financing facility announcement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions to fundamentally positive updates, with three instances of negative moves on good news and two strong positive responses.
Over the past several months, Beam has reported multiple positive clinical and financial milestones. BEACON Phase 1/2 data for risto-cel in sickle cell disease, including NEJM publication and expectations for a BLA by year-end 2026, and BEAM-302 data supporting pivotal development, have been key themes. Financial updates highlighted cash of about $1.2 billion and extended runway, plus new programs such as BEAM-304 for PKU. Against this backdrop, today’s conference appearance fits into an active period of clinical and corporate visibility.
Key Terms
base editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
